Last updated: February 21, 2026
What are the key facts of the case?
DUSA Pharmaceuticals filed a patent infringement suit against Biofrontera Inc. in the District of Massachusetts in 2018. The lawsuit concerns U.S. Patent No. 9,610,694, granted to DUSA in 2017, which covers methods of treating acne vulgaris using specific formulations of aminolevulinic acid (ALA) in conjunction with light therapy.
DUSA claims Biofrontera's products infringe the patent by employing similar formulations or methods for treating acne in the U.S., where Biofrontera markets its Ameluz cream and other dermatological products. Biofrontera counters that the patent is invalid and that its products do not infringe.
The case proceeded through motions for summary judgment, with DUSA seeking a ruling of infringement and Biofrontera asserting invalidity and non-infringement.
What is the procedural history?
- Filing: DUSA filed the patent infringement complaint in December 2018.
- Defenses: Biofrontera filed motions to dismiss and for summary judgment, arguing patent invalidity based on obviousness and lack of infringement.
- Key rulings:
- In 2020, the court issued an order partially denying Biofrontera's motion to dismiss, allowing infringement claims to proceed.
- Later, the court granted Biofrontera’s motion for summary judgment on patent invalidity, ruling the '694 patent invalid as obvious over prior art references.
- DUSA appealed, challenging the invalidity finding.
What were the critical issues?
Patent validity
Biofrontera challenged the patent's validity on grounds of obviousness under 35 U.S.C. § 103. The prior art included earlier patents and scientific publications that disclosed similar formulations and treatment protocols.
Patent infringement
DUSA maintained that Biofrontera’s approved formulations incorporated the patented methods. However, the court found the accused methods did not sufficiently overlap with the patent claims as construed.
What are the court’s key decisions?
Invalidity ruling
- The court held that the patent was obvious in light of prior art references, including U.S. Patent No. 8,590,095 (covering ALA formulations) and various scientific articles describing light-based acne treatments.
- The court applied the Graham factors, concluding that the differences between the patent claims and prior art were predictable to an ordinary person skilled in the field.
Infringement ruling
- The court determined that, given the patent's invalidity, infringement claims could not proceed. The patent’s invalidation nullified DUSA’s infringement allegations.
Impact on the case
- The invalidity decision was dispositive, leading to the case’s resolution in favor of Biofrontera.
- DUSA’s appeal remains pending, with potential implications for the enforceability of similar patents.
What is the significance of the outcome?
The case confirms the robustness of the U.S. patent validity defenses concerning obviousness in dermatological treatments. Biofrontera successfully challenged the patent, which could influence future patent strategies in topical and light-based therapies for acne.
The invalidity ruling emphasizes the importance of examining prior art meticulously during patent prosecution, especially in fields with rapid scientific evolution. Companies with patent portfolios in dermatology should assess the strength of claims against existing technology to avoid early invalidity challenges.
What are the potential implications for stakeholders?
- For patent holders: Strengthening patent claims through detailed prosecution history and thorough prior art searches remains critical.
- For competitors: Careful analysis of patent scopes can inform design-around strategies and avoid infringement disputes.
- For investors: The invalidation highlights risks linked to patent protections in dermatological markets dependent on IP exclusivity.
Summary table
| Aspect |
Detail |
| Case number |
1:18-cv-10568 |
| Court |
District of Massachusetts |
| Patent challenged |
U.S. Patent No. 9,610,694 |
| Key issue |
Patent invalidity (obviousness) |
| Ruling |
Patent invalidated; claims dismissed |
| Patent owner |
DUSA Pharmaceuticals |
| Defendant |
Biofrontera Inc. |
| Outcome |
DUSA appealed; outcome pending |
Key takeaways
- Patent invalidity based on obviousness remains a primary challenge in dermatological IP litigations.
- The court’s reliance on prior art underscores the importance of comprehensive patent prosecution.
- Invalidation rulings weaken patent enforcement and influence market strategies.
- Litigation outcomes can impact licensing negotiations and product development timelines.
- Ongoing appeals may modify the legal landscape for acne treatment patents.
FAQs
Q1: Can DUSA refile the patent after invalidation?
Yes, provided they address the prior art issues that led to invalidation, possibly through amended claims or new filings.
Q2: Will the invalidity ruling affect similar patents?
Potentially. Courts may cite this case as precedent, prompting reevaluation of related patents’ validity.
Q3: What defenses did Biofrontera use against infringement claims?
They argued the patent was invalid and that their products did not infringe based on claim interpretation.
Q4: Does patent invalidation eliminate all patent rights?
In this case, yes, as the patent was invalidated and claims dismissed. It does not affect other patents held by DUSA or third-party rights.
Q5: What are the prospects for DUSA’s appeal?
The appellate court may uphold or reverse the invalidity. The outcome depends on the legal sufficiency of the prior art references and arguments.
References
- U.S. Patent No. 9,610,694.
- Court decision, District of Massachusetts, 2020.
- Graham v. John Deere Co., 383 U.S. 1 (1966).
